Page last updated: 2024-08-24

milnacipran and paroxetine

milnacipran has been researched along with paroxetine in 40 studies

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.50)18.7374
1990's1 (2.50)18.2507
2000's26 (65.00)29.6817
2010's12 (30.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Baba, S; Horisawa, T; Kato, T; Kinomura, N; Kodo, T; Koyama, K; Masumoto, S; Matsumoto, K; Matsumoto, Y; Oki, H; Yabuuchi, K; Yoshinaga, H1
Briley, M; Moret, C1
Barone, P; Briley, M; Fillion, G; Moret, C1
Barbagli, B; Boissard, R; Fort, P; Gervasoni, D; Henninot, V; Luppi, PH; Panconi, E1
Koyama, T; Suzuki, K1
Arita, S; Morishita, S5
Nakamura, J; Okamoto, K; Shinkai, K; Ueda, N; Yoshimura, R1
Hemrick-Luecke, SK; Iyengar, S; Simmons, RM; Webster, AA; Xu, JY1
Cabanac, F; Pezous, N; Sechter, D; Tournoux, A; Vandel, P; Weiller, E1
Cabanac, F; Panconi, E; Pezous, N; Sechter, D; Tournoux, A; Vandel, P; Weiller, E1
Bourin, M; Hascoët, M; Massé, F1
Nakamura, J; Shinkai, K; Toyohira, Y; Tsutsui, M; Ueno, S; Yanagihara, N; Yoshimura, R2
Inoue, Y; Iwakawa, M; Kojima, H; Nakajima, M; Nakamura, J; Okamoto, T; Shinkai, K; Soya, A; Terao, T; Ueta, Y; Yoshimura, R1
Ikeda, K; Kobayashi, T; Washiyama, K1
Hori, H; Mitoma, M; Nakamura, J; Okamoto, T; Sugita, A; Ueda, N; Umene, W; Yoshimura, R1
Nomura, S; Sato, Y; Shigemura, J; Yoshino, A1
Baldwin, D; Briley, M; Moreno, RA1
Hori, H; Kodama, Y; Nakamura, J; Nakano, H; Sugita, A; Ueda, N; Umene, W; Yoshimura, R1
Azuma, J; Fukuda, T; Hosoi, Y; Kato, M; Kinoshita, T; Nonen, S; Okugawa, G; Takekita, Y; Wakeno, M; Yamashita, M1
Awa, Y; Hattori, T; Ito, T; Sakakibara, R; Uchiyama, T; Yamaguchi, C1
Abe, H; Ikeda, T; Ishida, Y; Nakamura, T; Naono, R; Nishimori, T; Takeda, R1
Chang, TT; Chen, YC; Lee, SY; Lêng, CH; Lu, RB; Wang, YS; Wu, JY1
Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T1
Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R1
Imai, S; Kuzumaki, N; Narita, M; Rahmadi, M; Suzuki, T; Yamashita, A1
Nagata, T; Nakajima, T; Teo, AR; van Vliet, I; Yamada, H; Yoshimura, C1
Azuma, J; Hasegawa, R; Hiratsuka, K; Ishiwata, K; Kato, M; Kinoshita, T; Kurosawa, T; Kurose, K; Nishikawa, J; Nonen, S; Okugawa, G; Saito, Y; Wakeno, M1
Chang, YH; Chen, PS; Chen, SH; Chen, SL; Cheng, LY; Chu, CH; Chuang, HY; Lee, IH; Lu, RB; Wang, YS; Yang, YK; Yeh, TL1
Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M1
Egashira, N; Kuwahara, J; Masuda, S; Ueda, M; Ushio, S; Yamada, T; Zukeyama, N1
Harada, S; Matsuura, W; Tokuyama, S1
Dudka, J; Poleszak, E; Serefko, A; Stasiuk, W; Świąder, K; Szopa, A; Wlaź, P; Wyska, E1

Reviews

2 review(s) available for milnacipran and paroxetine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Pharmacokinetics and drug interaction of antidepressants and anti-manic drugs].
    Ryoikibetsu shokogun shirizu, 2003, Issue:38

    Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antimanic Agents; Carbamazepine; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Interactions; Fluvoxamine; Humans; Isoenzymes; Lithium; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Valproic Acid

2003

Trials

12 trial(s) available for milnacipran and paroxetine

ArticleYear
Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Human psychopharmacology, 2004, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Chi-Square Distribution; Cohort Studies; Cyclopropanes; Depression; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2004
A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Journal of affective disorders, 2004, Volume: 83, Issue:2-3

    Topics: Adrenergic Uptake Inhibitors; Adult; Ambulatory Care; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychomotor Disorders; Reaction Time; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2004
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Human psychopharmacology, 2004, Volume: 19, Issue:8

    Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Cyclopropanes; Depressive Disorder; Double-Blind Method; Follow-Up Studies; Humans; Milnacipran; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Treatment Outcome

2004
Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers.
    Psychopharmacology, 2006, Volume: 187, Issue:4

    Topics: Adrenergic Uptake Inhibitors; Adrenocorticotropic Hormone; Adult; Brain; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Milnacipran; Norepinephrine; Paroxetine; Reference Values; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors

2006
Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Progress in neuro-psychopharmacology & biological psychiatry, 2007, Jun-30, Volume: 31, Issue:5

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cyclopropanes; Depressive Disorder; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors

2007
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran.
    Human psychopharmacology, 2008, Volume: 23, Issue:6

    Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Sexual Dysfunctions, Psychological; Surveys and Questionnaires

2008
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Asian People; Cyclopropanes; Depressive Disorder, Major; Female; Gene Expression Regulation; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, Adrenergic, alpha-2; Time Factors

2008
Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
    Urologia internationalis, 2008, Volume: 81, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Cyclopropanes; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Prospective Studies; Quality of Life; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics

2008
Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
    The Chinese journal of physiology, 2008, Dec-31, Volume: 51, Issue:6

    Topics: Adolescent; Adult; Aged; Asian People; Cyclopropanes; Depressive Disorder, Major; Follow-Up Studies; Humans; Middle Aged; Milnacipran; Molecular Structure; Paroxetine; Taiwan

2008
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Nov-13, Volume: 33, Issue:8

    Topics: Adult; Aged; Antidepressive Agents; Blood Platelets; Case-Control Studies; Cyclopropanes; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Middle Aged; Milnacipran; Nitric Oxide; Paroxetine; Statistics as Topic; Time Factors

2009
Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.
    The Chinese journal of physiology, 2014, Oct-31, Volume: 57, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride

2014
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
    Translational psychiatry, 2015, Feb-24, Volume: 5

    Topics: Age Factors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclopropanes; Depressive Disorder, Major; Female; Fibroblast Growth Factors; Fluvoxamine; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptors, Adrenergic, alpha-2; Serotonin Plasma Membrane Transport Proteins; Sex Factors; Treatment Outcome

2015

Other Studies

26 other study(ies) available for milnacipran and paroxetine

ArticleYear
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results

2011
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
    Bioorganic & medicinal chemistry, 2017, 01-01, Volume: 25, Issue:1

    Topics: Animals; Antidepressive Agents; Cytochrome P-450 CYP2D6 Inhibitors; Dioxanes; Drug Partial Agonism; Humans; Male; Piperidines; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Agonists; Serotonin Plasma Membrane Transport Proteins

2017
High- and low-affinity binding of [3H]imipramine in rat hypothalamus.
    Journal of neurochemistry, 1986, Volume: 47, Issue:5

    Topics: Amitriptyline; Animals; Citalopram; Clomipramine; Cyclopropanes; Hypothalamus; Imipramine; Kinetics; Male; Milnacipran; Paroxetine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Serotonin; Sodium

1986
Autoradiographic characterization of binding sites for [3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain.
    Brain research, 1994, Dec-30, Volume: 668, Issue:1-2

    Topics: 5,7-Dihydroxytryptamine; Animals; Autoradiography; Benzylamines; Binding Sites; Binding, Competitive; Biological Transport; Brain; Brain Chemistry; Cyclopropanes; Milnacipran; Paroxetine; Rats; Rats, Wistar; Serotonin Receptor Agonists; Tritium

1994
Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine.
    Pharmacology, biochemistry, and behavior, 2002, Volume: 73, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Animal; Body Weight; Cyclopropanes; Imipramine; Male; Milnacipran; Paroxetine; Rats; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Stages; Sleep, REM; Wakefulness

2002
Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Human psychopharmacology, 2003, Volume: 18, Issue:6

    Topics: Antidepressive Agents; Bipolar Disorder; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Outpatients; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome

2003
Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    European psychiatry : the journal of the Association of European Psychiatrists, 2003, Volume: 18, Issue:8

    Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Personality Inventory; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome

2003
Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:1

    Topics: Adult; Aged; Biomarkers; Cyclopropanes; Depressive Disorder; Female; Homovanillic Acid; Hospitals, University; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Milnacipran; Paroxetine; Patient Selection; Selective Serotonin Reuptake Inhibitors

2004
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:2

    Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cyclohexanols; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Duloxetine Hydrochloride; Fluoxetine; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Male; Methyltyrosines; Milnacipran; Neuromuscular Junction; Norepinephrine; p-Chloroamphetamine; Pain; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Thiophenes; Venlafaxine Hydrochloride

2004
Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine.
    European psychiatry : the journal of the Association of European Psychiatrists, 2004, Volume: 19, Issue:5

    Topics: Adult; Aged; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depression; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Prevalence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires

2004
Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2004, Volume: 19, Issue:7

    Topics: Cohort Studies; Cyclopropanes; Depression; Drug Administration Schedule; Fluvoxamine; Humans; Milnacipran; Paroxetine; Psychomotor Agitation; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires

2004
alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
    Behavioural brain research, 2005, Oct-14, Volume: 164, Issue:1

    Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Clonidine; Cyclohexanols; Cyclopropanes; Dose-Response Relationship, Drug; Drug Antagonism; Guanabenz; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Punishment; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Venlafaxine Hydrochloride

2005
Effect of prolonged exposure to milnacipran on norepinephrine transporter in cultured bovine adrenal medullary cells.
    Biochemical pharmacology, 2005, Nov-01, Volume: 70, Issue:9

    Topics: Adrenal Medulla; Adrenergic Uptake Inhibitors; Animals; Cattle; Cells, Cultured; Cycloheximide; Cyclopropanes; Dactinomycin; Desipramine; Gene Expression Regulation; Milnacipran; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; RNA, Messenger; Up-Regulation

2005
Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine.
    Journal of pharmacological sciences, 2006, Volume: 102, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Barium; Cyclopropanes; Electrophysiology; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Hydrogen-Ion Concentration; Milnacipran; Oocytes; Paroxetine; Plasmids; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptor, Adenosine A1; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors; Trazodone; Xenopus laevis

2006
Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran.
    Naunyn-Schmiedeberg's archives of pharmacology, 2007, Volume: 375, Issue:1

    Topics: Adrenal Medulla; Animals; Antidepressive Agents; Butadienes; Catecholamines; Cattle; Cells, Cultured; Cyclopropanes; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Enzyme Activation; Fluvoxamine; Milnacipran; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Paroxetine; Phosphorylation; Protein Kinase Inhibitors; Selective Serotonin Reuptake Inhibitors; Time Factors; Tyrosine; Tyrosine 3-Monooxygenase

2007
Patient satisfaction with antidepressants: an Internet-based study.
    Journal of affective disorders, 2008, Volume: 107, Issue:1-3

    Topics: Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclopropanes; Data Collection; Depressive Disorder, Major; Fluvoxamine; Humans; Internet; Japan; Logistic Models; Milnacipran; Paroxetine; Patient Satisfaction; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires

2008
Two cases of burning mouth syndrome treated with olanzapine.
    Psychiatry and clinical neurosciences, 2008, Volume: 62, Issue:3

    Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Burning Mouth Syndrome; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Milnacipran; Olanzapine; Paroxetine; Treatment Outcome

2008
Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain.
    Neuroscience research, 2009, Volume: 63, Issue:1

    Topics: Analgesics; Animals; Antidepressive Agents; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Fluvoxamine; Hyperalgesia; Injections, Spinal; Male; Milnacipran; Pain Threshold; Paroxetine; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sciatic Neuropathy; Selective Serotonin Reuptake Inhibitors; Serotonin; Spinal Cord

2009
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
    Neuroscience research, 2009, Volume: 64, Issue:3

    Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger

2009
Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran.
    Synapse (New York, N.Y.), 2011, Volume: 65, Issue:7

    Topics: Animals; Brain; Cyclopropanes; Electroencephalography; Electromyography; Histamine; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Milnacipran; Neuropeptides; Orexin Receptors; Orexins; Paroxetine; Receptors, Histamine; Receptors, Neuropeptide; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Wake Disorders; Synaptic Transmission

2011
Comorbid social withdrawal (hikikomori) in outpatients with social anxiety disorder: clinical characteristics and treatment response in a case series.
    The International journal of social psychiatry, 2013, Volume: 59, Issue:1

    Topics: Adolescent; Adult; Anti-Anxiety Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclopropanes; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluvoxamine; Humans; Interview, Psychological; Japan; Male; Milnacipran; Obsessive-Compulsive Disorder; Paroxetine; Phobic Disorders; Psychotherapy, Group; Reactive Attachment Disorder; Retrospective Studies; Social Isolation; Treatment Outcome; Young Adult

2013
Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.
    Psychiatry research, 2012, Aug-15, Volume: 198, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Asian People; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Genome-Wide Association Study; Genotype; GPI-Linked Proteins; Humans; Male; Middle Aged; Milnacipran; Neural Cell Adhesion Molecules; Paroxetine; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological

2012
Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells.
    Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Citalopram; Cyclopropanes; Duloxetine Hydrochloride; Fluvoxamine; Hep G2 Cells; Humans; Liver Neoplasms; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline

2015
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:5

    Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain Ischemia; Carbamazepine; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Cyclopropanes; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Imipramine; Indomethacin; Male; Mexiletine; Mice; Milnacipran; Morphine; Neuralgia; Paroxetine; Selective Serotonin Reuptake Inhibitors

2016
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2017, Volume: 124, Issue:3

    Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Bupropion; Chromatography, High Pressure Liquid; Cyclopropanes; Depressive Disorder; Desipramine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Piperidines; Receptors, N-Methyl-D-Aspartate

2017